Eidos Therapeutics (Eidos Therapeutics) Cash Conversion Cycle : 0.00 (As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Eidos Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2020 was 0.
Eidos Therapeutics's Days Inventory for the three months ended in Sep. 2020 was 0.
Eidos Therapeutics's Days Payable for the three months ended in Sep. 2020 was 0.
Therefore, Eidos Therapeutics's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2020 was 0.00.

Eidos Therapeutics Cash Conversion Cycle Historical Data

The historical data trend for Eidos Therapeutics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Cash Conversion Cycle Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Cash Conversion Cycle

-372.81

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Cash Conversion Cycle	Get a 7-Day Free Trial											-98.71	-	-	-	-

Competitive Comparison of Eidos Therapeutics's Cash Conversion Cycle

For the Biotechnology subindustry, Eidos Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eidos Therapeutics's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's Cash Conversion Cycle falls into.

Eidos Therapeutics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Eidos Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2019 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	372.81
	=	-372.81

Eidos Therapeutics's Cash Conversion Cycle for the quarter that ended in Sep. 2020 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	0
	=	0.00

Eidos Therapeutics (NAS:EIDX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Eidos Therapeutics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (Eidos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Executives

Uma Sinha	director, officer: Chief Scientific Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle	officer: Senior Vice President, Finance	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle	officer: Chief Business Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox	officer: See Remarks	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen	director	3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat	director, 10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu	officer: CFO and Secretary	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc.	10 percent owner	421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar	director, 10 percent owner, officer: Chief Executive Officer	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116